Pharmafile Logo
Pharmafocus logo
Advanced Search

patent cliff

Showing 6 posts of 6 posts found.

pharma manufacturing

‘Rejuvenated’ pharma manufacturing set for 2016 comeback

January 4, 2016
Manufacturing and Production, Sales and Marketing Employment, industry, manufacturing, patent cliff, pharma, production

The pharma industry has been singled out for its strong performance in 2015, in a report which says manufacturing in …

News
Coins

ANALYSIS: The challenges of forecasting biosimilar sales across Europe

October 29, 2015
Manufacturing and Production, Research and Development, Sales and Marketing biologics, biosimilars, generics, patent cliff, patents, sales, sales forecasts

The introduction of biologic medicines revolutionised treatment in several key therapeutic areas, including oncology, diabetes and various inflammatory diseases.The landscape …

Feature
BGMA D-G Warwick Smith

OPINION: ‘More work remains if biosimilars are to fulfil their potential’

October 27, 2015
Manufacturing and Production, Research and Development, Sales and Marketing British Generic Manufacturers Association, NHS, bgma, biosimilars, generics, patent cliff, patents

Despite having a mature generics market which fulfils more than three-quarters of all prescriptions in the UK, and as a …

Feature
Humira

Future Focus: The industry’s top five biggest drug patent expirations in 2016

October 21, 2015
Manufacturing and Production, Research and Development biosimilars, blockbuster, generics, patent cliff, patents

From Humira to Cubicin, some multi-billion dollar drugs are set to be hit hard by patent expiries next year, and …

Feature
Daiichi Sankyo

Daiichi sheds more US jobs as generic losses take their toll

October 20, 2015
Daiichi, Daiichi Sankyo, generic competition, generics, job losses, patent cliff, patents, redundancies

The Japan-based drugmaker Daiichi Sankyo is to cut up to 1,200 jobs – or about half its workforce – in …

News
sanofi image

Diabetes softens generics blow for Sanofi

October 30, 2012
Sales and Marketing Eloxatin, Plavix, Sanofi, diabetes, emerging markets, patent cliff

Sanofi has unveiled its results for the third quarter, with news that the damage done by patent expiries has not …

News

Latest content

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024